Log in

Relevant bibliographies by topics / Liposarcoma-associated / Journal articles

Journal articles on the topic 'Liposarcoma-associated'

To see the other types of publications on this topic, follow the link: Liposarcoma-associated.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Liposarcoma-associated.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Matsumoto, Keiji, Sinsuke Hukuda, Michihito Ishizawa, Masaaki Egawa, and Hidetoshi Okabe. "Liposarcoma Associated With Multiple Intramuscular Lipomas." Clinical Orthopaedics and Related Research 373 (April 2000): 202–7. http://dx.doi.org/10.1097/00003086-200004000-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Matzinger, Oscar. "Spermatic Cord Liposarcoma Associated with Prostate Cancer." International Journal of Hematology and Oncology 21, no. 4 (December 31, 2011): 241–44. http://dx.doi.org/10.4999/uhod.09130.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kanzaki, Masato, Takamasa Onuki, Masahide Murasugi, Hiroko Fukuda, Takayuki Tatebayashi, Shohei Yuasa, Susumu Sasano, Hideto Kaneyu, Masayoshi Yokoyama, and Sumio Nitta. "Liposarcoma associated with dyspnea; a case report." Journal of the Japanese Association for Chest Surgery 9, no. 1 (1995): 96–100. http://dx.doi.org/10.2995/jacsurg.9.96.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Shinder, Roman, David Mostafavi, Qasiem J. Nasser, Bita Esmaeli, and John W. Shore. "Primary Orbital Liposarcoma Misdiagnosed as Thyroid Associated Orbitopathy." Orbit 31, no. 4 (May 9, 2012): 264–66. http://dx.doi.org/10.3109/01676830.2011.632112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ballesteros, F., Juan Jose Sanz, Jose Maria Guilemany, M. Moragas, A. Gaspa, and M. Bernal-Sprekelsen. "Bulky cervical liposarcoma associated with sleep apnea syndrome." Acta Oto-Laryngologica 126, no. 2 (January 2006): 209–13. http://dx.doi.org/10.1080/00016480500266784.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

de Raucourt, E., M. D. Dumont, J. M. Tourani, J. P. Hubsch, M. Riquet, and A. M. Fischer. "Acquired factor VII deficiency associated with pleural liposarcoma." Blood Coagulation & Fibrinolysis 5, no. 5 (October 1994): 833–36. http://dx.doi.org/10.1097/00001721-199410000-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gimber, L. H., E. A. Montgomery, C. D. Morris, E. A. Krupinski, and L. M. Fayad. "MRI characteristics associated with high-grade myxoid liposarcoma." Clinical Radiology 72, no. 7 (July 2017): 613.e1–613.e6. http://dx.doi.org/10.1016/j.crad.2017.01.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kiyosawa, Tomoharu, Hitoshi Higaki, and Yoshio Nakayama. "Liposarcoma associated with fever and reversible hepatic dysfunction." International Journal of Dermatology 36, no. 2 (June 28, 2008): 132–34. http://dx.doi.org/10.1111/j.1365-4362.1997.tb03073.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fitzgerald, Katie, Eliza M. Slama, and Irina Bernescu. "Dedifferentiated Liposarcoma of the Transverse Colon." American Surgeon 88, no. 4 (November 2, 2021): 790–92. http://dx.doi.org/10.1177/00031348211054524.

Full text

Abstract:

While liposarcoma is one of the most common soft tissue sarcomas, it is rarely seen within the gastrointestinal tract, and even less frequently seen within the colon. Dedifferentiated liposarcoma is a subtype of liposarcoma, which along with the pleomorphic subtype is considered a high-grade, aggressive tumor; both possess the ability to metastasize and are associated with decreased survival. Despite complete resection, recurrence is common. While surgical excision is the cornerstone of treatment for liposarcoma of the colon, there is no consensus on adjuvant therapies. We present the case of a 66-year-old woman who presented with abdominal pain with rectal bleeding and was found on colonoscopy to have a high-grade dedifferentiated liposarcoma of the transverse colon. She underwent robotic segmental colectomy. Due to absence of nodal involvement or distal metastasis, adjuvant therapy was not administered. On 1-year follow-up, the patient remains disease free.

APA, Harvard, Vancouver, ISO, and other styles

10

Suzuki, Takahiro, Kazuhiro Murakami, Naoya Noguchi, Fumi Shoji, Sachiko Fukaya, Yutaka Tateda, Muneharu Yamazaki, Miho Nakazumi, Teruyuki Sato, and Nobuo Ohta. "Pleomorphic liposarcoma arising on the cheek: a case report and review of the literature." International Journal of Otorhinolaryngology and Head and Neck Surgery 7, no. 9 (August 23, 2021): 1526. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20213292.

Full text

Abstract:

<p class="abstract">Pleomorphic liposarcoma, which is the rarest of the four liposarcoma types according to the World Health Organization (WHO) classification of soft tissue tumors, is associated with a high rate of recurrence and poor prognosis. In the present report, we present the case of a 69-year-old male patient with pleomorphic liposarcoma arising in the right cheek. The mass was initially considered as benign such as schwannoma due to the absence of facial nerve palsy. However, the mass grew rapidly, requiring surgical removal with facial nerve preservation. Pathological and molecular examination led to the definitive diagnosis of pleomorphic liposarcoma. The postoperative adjuvant radiotherapy was added, and there were no signs of recurrence at four-year follow-up.</p>

APA, Harvard, Vancouver, ISO, and other styles

11

Lee, Alex Thomas John, Khin Thway, Paul H. Huang, and Robin Lewis Jones. "Clinical and Molecular Spectrum of Liposarcoma." Journal of Clinical Oncology 36, no. 2 (January 10, 2018): 151–59. http://dx.doi.org/10.1200/jco.2017.74.9598.

Full text

Abstract:

Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology encompassed by these diseases. Increasingly, clinical management decisions and the development of investigational therapeutics are informed by an improved understanding of subtype-specific molecular pathology. Well-differentiated liposarcoma is the most common subtype and is associated with indolent behavior, local recurrence, and insensitivity to radiotherapy and chemotherapy. Dedifferentiated liposarcoma represents focal progression of well-differentiated disease into a more aggressive, metastasizing, and fatal malignancy. Both of these subtypes are characterized by recurrent amplifications within chromosome 12, resulting in the overexpression of disease-driving genes that have been the focus of therapeutic targeting. Myxoid liposarcoma is characterized by a pathognomonic chromosomal translocation that results in an oncogenic fusion protein, whereas pleomorphic liposarcoma is a karyotypically complex and especially poor-prognosis subtype that accounts for less than 10% of liposarcoma diagnoses. A range of novel pharmaceutical agents that aim to target liposarcoma-specific biology are under active investigation and offer hope of adding to the limited available treatment options for recurrent or inoperable disease.

APA, Harvard, Vancouver, ISO, and other styles

12

Miron, Ingrid, Gabriel Aprodu, Doina Mihaila, Petru Plamadeala, Oana Tatiana Miron, Anamaria Ciubara, Lucian Miron, Marin Burlea, Stefana Maria Moisa, and Laurentiu Lucaci. "Primary bone liposarcoma in children." Romanian Journal of Pediatrics 63, no. 3 (September 30, 2014): 285–87. http://dx.doi.org/10.37897/rjp.2014.3.12.

Full text

Abstract:

Introduction. Even though the soft tissue liposarcoma is a frequent tumor, the primary bone liposarcoma is very rare, being localized especially in the long bones. Material and method. We present the case of a 14 years old female child, hospitalized in the „Sf. Maria“ Emergency Clinic Hospital for Children Iasi accusing pain, functional impairment and tumefaction in the right arm, symptoms which suddenly occurred about 24 hours prior to presentation, following a falling trauma on the right arm. The bone x-ray emphasized a tumor in the proximal part of the humerus bone, associated with a pathological fracture. Results. A biopsy form the tumor was performed and the pathology report (histology and immunohistochemistry) documented a malignant liposarcomatous proliferation. Conclusion. The final pathology diagnosis, correlated with the clinical findings, which excluded the possibility of a bone metastasis, was that of a primary bone liposarcoma. Case particularity: very rare tumor, witch presented with a pathological bone fracture. In establishing the diagnosis of a bone liposarcoma it is very important to exclude a bone metastasis from a liposarcoma with a primary localization other than the bone, as well as other primary bone tumors. The prognosis seems to be better than in the osteosarcoma but liposarcoma presents a higher rate of local recurrence and systemic dissemination.

APA, Harvard, Vancouver, ISO, and other styles

13

Cervi, David, Tai-Tung Yip, Nandita Bhattacharya, Vladimir N. Podust, Jon Peterson, Abdo Abou-Slaybi, George N. Naumov, et al. "Platelet-associated PF-4 as a biomarker of early tumor growth." Blood 111, no. 3 (February 1, 2008): 1201–7. http://dx.doi.org/10.1182/blood-2007-04-084798.

Full text

Abstract:

AbstractEarly tumor detection and intervention are important determinants of survival in patients with cancer. We have recently reported that the “platelet angiogenesis proteome” may be used to detect microscopic tumors in mice. We now present evidence that changes in platelet-associated platelet factor-4 (PF-4) detect malignant growth across a spectrum of human cancers in mice. A deregulated expression of an 8206-Da protein was observed by surfaceenhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-ToF MS) proteomic comparison of platelets from normal and tumor-bearing mice. The differentially expressed protein was identified as PF-4 by tandem mass spectrometry and ProteinChip immunoassay using anti–PF-4 antibody. The platelet-associated PF-4 appeared to be up-regulated in early growth of human liposarcoma, mammary adenocarcinoma, and osteosarcoma. A 120-day follow-up study of liposarcoma revealed a sustained 2-fold or higher increase of platelet-associated PF-4 at 19, 30, and 120 days. In contrast, only an insignificant change of PF-4 was observed in the plasma of mice bearing the different human tumor xenografts, and throughout the 120 days of the liposarcoma study. We conclude that platelet-associated PF-4, but not its plasma counterpart, may represent a potential biomarker of early tumor presence.

APA, Harvard, Vancouver, ISO, and other styles

14

Penmetcha, Akhil, Jela Bandovic, and Lionel D'Souza. "S1916 Liposarcoma Associated with Fibrovascular Polyp of the Esophagus." American Journal of Gastroenterology 115, no. 1 (October 2020): S995. http://dx.doi.org/10.14309/01.ajg.0000709712.80758.f5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Morishima, Ryo, Takayuki Kato, Tatsuki Aki, Mitsunori Ishiguro, Shin-ichi Sirakami, and Shu Imai. "A Case of Liposarcoma Brain Metastasis associated with Intracerebral Hemorrhage." Japanese Journal of Neurosurgery 30, no. 9 (2021): 680–86. http://dx.doi.org/10.7887/jcns.30.680.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Lewis, Donald J., Judd W. Moul, Scott C. Williams, Isabell A. Sesterhenn, and Edgar Colon. "Perirenal liposarcoma containing extramedullary hematopoiesis associated with renal cell carcinoma." Urology 43, no. 1 (January 1994): 106–9. http://dx.doi.org/10.1016/s0090-4295(94)80279-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Liu, Jianwei, Rong Li, Xiwen Liao, and Weiping Jiang. "Comprehensive Bioinformatic Analysis Genes Associated to the Prognosis of Liposarcoma." Medical Science Monitor 24 (October 14, 2018): 7329–39. http://dx.doi.org/10.12659/msm.913043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Yohannan, Binoy, Arthi Sridhar, Johncy John Kachira, and Syed H. Jafri. "Glutamic acid decarboxylase (GAD) antibody-positive paraneoplastic stiff person syndrome associated with mediastinal liposarcoma." BMJ Case Reports 15, no. 7 (July 2022): e250639. http://dx.doi.org/10.1136/bcr-2022-250639.

Full text

Abstract:

Stiff person syndrome (SPS) is a rare, debilitating neurological illness characterised by rigidity and spasms of the axial muscles, causing severe restrictions to mobility. SPS can be classic, partial or paraneoplastic. We report a case of a young woman who presented with seizures and painful spasms of the thoracolumbar muscles who was subsequently diagnosed with SPS. Serological work revealed glutamic acid decarboxylase (GAD) antibodies and imaging showed a large mediastinal mass. The patient underwent surgical resection of the mediastinal mass and final pathology revealed well-differentiated mediastinal liposarcoma. She received five sessions of plasma exchange and her neurological symptoms gradually improved after surgery. This case highlights a rare case of GAD antibody-positive paraneoplastic SPS associated with mediastinal liposarcoma.

APA, Harvard, Vancouver, ISO, and other styles

19

Fanburg-Smith, J. C., and M. Miettinen. "Liposarcoma with meningothelial-like whorls: a study of 17 cases of a distinctive histological pattern associated with dedifferentiated liposarcoma." Histopathology 33, no. 5 (November 1998): 414–24. http://dx.doi.org/10.1046/j.1365-2559.1998.00536.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Angeles, Christina V., Jichang Han, Jodi Wilkoswki, and Scott Bresler. "Abstract A007: Resident memory T cells express PD-1 in high grade liposarcoma." Clinical Cancer Research 28, no. 18_Supplement (September 15, 2022): A007. http://dx.doi.org/10.1158/1557-3265.sarcomas22-a007.

Full text

Abstract:

Abstract Objective: Memory T cells play crucial roles in anti-tumor immunity. Tumor-associated resident memory T cells (TRM) have been associated with durable immune response and improved patient survival across multiple tumor types. SARC028, a phase II, multicenter trial of pembrolizumab, a programmed death 1 (PD-1) checkpoint inhibitor immunotherapy, showed promising activity in select histologic subtypes of advanced soft tissue sarcoma (STS), including dedifferentiated liposarcoma (DDLPS). However, there was only a 20% overall response rate. Notably, the patients who did respond to immunotherapy had durable responses, supporting our enthusiasm to understand the potential role for TRM in liposarcoma anti-tumor immunity. The characterization of memory T cells in liposarcoma, and whether TRM are present has not been explored. Design: Fresh retroperitoneal liposarcoma specimens from 8 patients: 3 well-differentiated liposarcoma (WDLPS) and 5 DDLPS were collected. Lymphocytes were analyzed by flow cytometry using T-cell (CD45, CD3, CD4, CD8) and phenotypic markers (CD69, CD62L, CD103, CD49a, PD-1, TIM-3). Results: DDLPS had a 4-fold higher overall T-cell infiltration and a 2.5-fold higher CD8+/CD4+ T-cell ratio than WDLPS. DDLPS contained CD8+ T cells with a CD45RA− CCR7− CD69hi CD62Llo phenotype, characteristic of a TRM response, and well as CD69lo effector memory T (TEM) cells. DDLPS had 3-fold more TRM than WDLPS. DDLPS had a much higher level of activated PD-1+ CD69+ CD8+ resident memory T-cell population compared to WDLPS. Additionally, the population of TRM had higher PD-1 expression compared to TEM in both DDLPS and WDLPS. Conclusions: These data suggest that TRM subsets may contribute to the responsiveness to anti-PD1 therapy in patients with DDLPS. Further investigations may lead to the discovery of TRM-targeted T-cell therapies in DDLPS, which currently has limited treatment options. Citation Format: Christina V. Angeles, Jichang Han, Jodi Wilkoswki, Scott Bresler. Resident memory T cells express PD-1 in high grade liposarcoma [abstract]. In: Proceedings of the AACR Special Conference: Sarcomas; 2022 May 9-12; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(18_Suppl):Abstract nr A007.

APA, Harvard, Vancouver, ISO, and other styles

21

Wu, Hongzeng, Qianqian Zhang, Yi Zhao, Fengzhou Xu, Jinming Zhang, Hongyan He, Xu Wang, and Helin Feng. "Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma." Journal of International Medical Research 48, no. 6 (June 2020): 030006052092635. http://dx.doi.org/10.1177/0300060520926355.

Full text

Abstract:

Objectives A relationship exists between sirtuin-1 expression and growth and survival of malignant tumors. This study aimed to investigate the prognostic value of sirtuin-1 and vascular endothelial growth factor (VEGF) expression in patients with liposarcoma by examining associations between their expression levels and clinical outcomes. Methods Clinical and histopathological characteristics and follow-up and survival information were retrospectively reviewed for 42 liposarcoma cases. Sirtuin-1 and VEGF protein expression levels were evaluated by immunohistochemistry and their associations with clinical parameters were analyzed using the Spearman-rho test. Univariate and multivariate Cox regression analyses were performed to identify potential prognostic factors. Kaplan–Meier analysis was performed to analyze overall survival. Results Sirtuin-1 and VEGF protein expression levels were significantly associated with histological grade, metastasis, and American Joint Committee on Cancer stage. A significant positive correlation was observed between sirtuin-1 and VEGF expression levels (R = 0.677). In univariate analysis, sirtuin-1 and VEGF expression were correlated with shorter overall survival, but the association was significant only for sirtuin-1 (hazard ratio = 3.752, 95% confidence interval 1.553–9.062) in multivariate analysis. Conclusion Sirtuin-1 and VEGF expression levels are significantly correlated with progression of liposarcoma, and sirtuin-1 expression significantly predicts a poor prognosis in patients with liposarcoma.

APA, Harvard, Vancouver, ISO, and other styles

22

Albagoush, Sara, Jonathan Gootee, Kevin Nguyen, Sarah J. Aurit, Christina Curtin, and Peter T. Silberstein. "The importance of surgical margins in dedifferentiated liposarcoma survival." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e22528-e22528. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e22528.

Full text

Abstract:

e22528 Background: Among the types of soft tissue sarcomas (STS), liposarcoma is the most common malignant STS. Considering therapeutic options, surgical resection is the most utilized therapeutic option. In this study, we aim to explore the effects of varying degrees of surgical margins on survival in patients with dedifferentiated liposarcoma. Methods: The National Cancer Database (NCDB) was used to select patients with dedifferentiated liposarcoma to determine if surgical margins and other variables were associated with worse overall survival after accounting for age, gender, race, Charlson-Deyo score, anatomic site, treatment approach, tumor size, tumor grade, and presence of metastases through multivariable analysis. Results: Of the 1,004 patients, 64.4% were male, 87.0% were white, and the median age was 63 years. Approximately 95% had no metastases at the time of diagnosis, and 91.5% had high grade liposarcoma. For the status of surgical margins, 50.8% had no residual tumors, 26.1% had microscopic residual tumors, and 4.3% had macroscopic residual tumors. In general, the risk of death was higher for older males (25.8% increased risk of mortality) and those with metastases (312.9% increased risk of mortality) as well as patients with high grade liposarcoma (112.4% increased risk of mortality). When compared to no residual tumor after surgery, patients with macroscopic residual tumors, had a 96.7% increased risk of death (HR 95% CI:1.24 to 3.13; p= 0.004). Conclusions: Older age, presence of metastasis, male patients, retroperitoneal/abdomen primary site, high grade tumors, and macroscopic or residual tumor present after surgery led to an increased risk of mortality.

APA, Harvard, Vancouver, ISO, and other styles

23

Nishio, Jun. "Contributions of Cytogenetics and Molecular Cytogenetics to the Diagnosis of Adipocytic Tumors." Journal of Biomedicine and Biotechnology 2011 (2011): 1–9. http://dx.doi.org/10.1155/2011/524067.

Full text

Abstract:

Over the last 20 years, a number of tumor-specific chromosomal translocations and associated fusion genes have been identified for mesenchymal neoplasms including adipocytic tumors. The addition of molecular cytogenetic techniques, especially fluorescence in situ hybridization (FISH), has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal translocations and/or other rearrangements in adipocytic tumors. Indeed, most resent molecular cytogenetic analysis has demonstrated a translocation t(11;16)(q13;p13) that produces aC11orf95-MKL2fusion gene in chondroid lipoma. Additionally, it is well recognized that supernumerary ring and/or giant rod chromosomes are characteristic for atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma, and amplification of 12q13–15 involving theMDM2,CDK4, andCPMgenes is shown by FISH in these tumors. Moreover, myxoid/round cell liposarcoma is characterized by a translocation t(12;16)(q13;p11) that fuses theDDIT3andFUSgenes. This paper provides an overview of the role of conventional cytogenetics and molecular cytogenetics in the diagnosis of adipocytic tumors.

APA, Harvard, Vancouver, ISO, and other styles

24

Kåbjörn Gustafsson, Christina, Anders Ståhlberg, Katarina Engtröm, Anna Danielsson, Ingela Turesson, and Pierre Åman. "Cell Senescence in Myxoid/Round Cell Liposarcoma." Sarcoma 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/208786.

Full text

Abstract:

Myxoid/round cell liposarcoma (MLS/RCLS) is the second most common liposarcoma type and characterized by the fusion oncogenesFUS-DDIT3orEWSR1-DDIT3. Previous analysis of cell cycle regulatory proteins revealed a prominent expression of G1-cyclins, cyclin dependent kinases, and their inhibitors but very few cells progressing through the G1/S boundary. Here, we extend the investigation to proteins involved in cell senescence in an immunohistochemistry based study of 17 MLS/RCLS cases. Large subpopulations of tumor cells expressed the RBL2 pocket protein and senescence associated heterochromatin 1γand IL8 receptorβ. We conclude that MLS/RCLS tissues contain major populations of senescent tumor cells and this may explain the slow growth rate of this tumor type.

APA, Harvard, Vancouver, ISO, and other styles

25

TAKAGI, Makoto, Toshiaki AOKI, Yuichi FUKAZAWA, Hidenori TOMIOKA, Toru SAGUCHI, and Makoto MOCHIZUKI. "A CASE OF MESENTERIC SOLITARY FIBROUS TUMOR ASSOCIATED WITH RETROPERITONEAL LIPOSARCOMA." Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 65, no. 3 (2004): 822–27. http://dx.doi.org/10.3919/jjsa.65.822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Shannon, Nicholas Brian, Qiu Xuan Tan, Joey Wee-Shan Tan, Josephine Hendrikson, Wai Har Ng, Gillian Ng, Ying Liu, et al. "Gene Expression Changes Associated with Dedifferentiation in Liposarcoma Predict Overall Survival." Cancers 13, no. 12 (June 18, 2021): 3049. http://dx.doi.org/10.3390/cancers13123049.

Full text

Abstract:

Up to 10% of well-differentiated liposarcoma (WDLS) progress to dedifferentiated liposarcoma (DDLS). We aimed to identify gene expression changes associated with dedifferentiation and whether these were informative of tumour biology of DDLS. We analysed datasets from the Gene Expression Omnibus (GEO, ID = GSE30929) database to identify differentially expressed genes between WDLS (n = 52) and DDLS (n = 39). We validated the signature on whole and laser-capture microdissected samples from patients with tumours consisting of mixed WDLS and DDLS components. A subset of this signature was applied to an independent dataset from The Cancer Genome Atlas (TCGA, n = 58 DDLS) database to segregate samples based on gene expression and compared for recurrence and overall survival (OS). A 15-gene signature consisting of genes with increased expression in DDLS compared to WDLS was generated. This signature segregated WDLS and DDLS samples from patients with mixed component tumours and across multiple recurrences. A further subset of this signature, consisting of five genes (AQP7, ACACB, FZD4, GPD1, LEP), segregated DDLS in a TCGA cohort with a significant difference in OS (p = 0.019) and recurrence-free survival (RFS) (p = 0.061). The five-gene model stratified DDLS into prognostic groups and outperformed clinical factors in existing models in retroperitoneal DDLS.

APA, Harvard, Vancouver, ISO, and other styles

27

Zhou, Liang, Xin Wei, Nian-Wei Wu, Han-Mei Zhang, Bang-Hua Liao, Shu-Lian Chen, Hong Li, Yu-Chun Zhu, and Kun-Jie Wang. "Paraneoplastic Cerebellar Degeneration Associated with Pelvic Liposarcoma: A Rare Case Report." Urologia Internationalis 100, no. 3 (January 17, 2017): 364–67. http://dx.doi.org/10.1159/000452167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Almog, Nava, Vanessa Henke, Ludmila Flores, Lynn Hlatky, Andrew L. Kung, Renee D. Wright, Raanan Berger, et al. "Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis." FASEB Journal 20, no. 7 (April 25, 2006): 947–49. http://dx.doi.org/10.1096/fj.05-3946fje.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Tomas, Xavier, Josep Maria Campistol, Joan Fontdevila, Jaume Pomes, and Alex Soriano. "Axillary lymphadenitis associated with a herpes-zoster mimicking a liposarcoma: MRI findings." Medicina Clínica (English Edition) 156, no. 12 (June 2021): 637. http://dx.doi.org/10.1016/j.medcle.2020.05.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Shimada, Shio, Hiroshi Harada, Keisuke Ishizawa, and Takanori Hirose. "Retroperitoneal lipomatous angiomyolipoma associated with amyloid deposition masquerading as well-differentiated liposarcoma." Pathology International 56, no. 10 (October 2006): 638–41. http://dx.doi.org/10.1111/j.1440-1827.2006.02021.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Yozu, Masato, Pennie Symmans, Michael Dray, Jennifer Griffin, Catherine Han, Daniel Ng, Susan Parry, and K. P. Wong. "Muir–torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field." Pathology 45 (2013): S88. http://dx.doi.org/10.1097/01.pat.0000426961.06488.f5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Yozu, Masato, Pennie Symmans, Michael Dray, Jennifer Griffin, Catherine Han, Daniel Ng, Susan Parry, and KP Wong. "Muir–Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field." Virchows Archiv 462, no. 3 (January 9, 2013): 355–60. http://dx.doi.org/10.1007/s00428-012-1369-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Mantilla, Jose G., Robert W. Ricciotti, Eleanor Y. Chen, Yajuan J. Liu, and Benjamin L. Hoch. "Amplification of DNA damage-inducible transcript 3 (DDIT3) is associated with myxoid liposarcoma-like morphology and homologous lipoblastic differentiation in dedifferentiated liposarcoma." Modern Pathology 32, no. 4 (November 12, 2018): 585–92. http://dx.doi.org/10.1038/s41379-018-0171-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Park, Jong Woong, Han-Soo Kim, Cheol Lee, Hye Jin Yoo, Ji Yeon Yun, and Ilkyu Han. "Preoperative Factors Associated with Infiltrative Histologic Growth Patterns in Extremity Soft Tissue Sarcoma." Sarcoma 2017 (2017): 1–8. http://dx.doi.org/10.1155/2017/5419394.

Full text

Abstract:

Soft tissue sarcoma (STS) with an infiltrative histologic growth pattern, when compared to STS with an expansile pattern, may pose difficulties in local control. Preoperative assessment of the presence of infiltrative histologic growth pattern would be helpful in deciding treatment strategies. A review of 144 patients who underwent surgery for extremity STS was performed. Microscopically, the histologic growth pattern was defined as infiltrative if the penetration of the tumor cells into the surrounding tissue was observed. Possible clinicopathologic factors that might be associated with infiltrative histologic growth pattern were investigated with regard to patient demographics, tumor characteristics, and MRI findings. Of the 144 tumors, 71 (49%) showed infiltrative histologic growth pattern. On multivariate analysis, histological subtypes other than liposarcoma (OR = 4.57, p=0.02) and infiltrative border on MRI (OR = 2.48, p=0.01) were independent factors associated with infiltrative histologic growth pattern. Predictive index based on these two factors showed a significant improved accuracy (ROC-AUC = 0.647) for predicting infiltrative histologic growth pattern compared to either factor alone. Our data suggests that liposarcoma histology and tumor border on MRI can predict histologic growth pattern in extremity STS.

APA, Harvard, Vancouver, ISO, and other styles

35

Linehan, David C., Jonathan J. Lewis, Denis Leung, and Murray F. Brennan. "Influence of Biologic Factors and Anatomic Site in Completely Resected Liposarcoma." Journal of Clinical Oncology 18, no. 8 (April 8, 2000): 1637–43. http://dx.doi.org/10.1200/jco.2000.18.8.1637.

Full text

Abstract:

PURPOSE: Soft tissue sarcoma (STS) encompasses a group of neoplasms that are anatomically and biologically diverse. Retroperitoneal/visceral (RP/V) tumors have a poorer prognosis than extremity/trunk (E/T) lesions, and this has been attributed to frequent presentation with tumors of large size and multiorgan involvement that precludes complete resection. The worse prognosis that is associated with RP/V tumors has also been thought to be histopathologically dependent and not necessarily related to anatomic site. The aim of this study was to determine the role of anatomic site and biologic features in prognosis and outcome in patients after complete resection by examining a large cohort of STS patients with a single histopathology, ie, liposarcoma. METHODS: All patients who were treated for liposarcoma from July 1, 1982, through July 1, 1998, were included. Univariate analyses were performed using log-rank test and Kaplan-Meier estimates, and multivariate analyses were performed using Cox regression. The three end points examined were local recurrence (LR), distant recurrence, and disease-specific survival (DSS). RESULTS: Seven hundred twenty patients with liposarcoma were evaluated, and of these, 460 had completely resected primary or completely resected locally recurrent disease. Breakdown of anatomic site was 65% E/T (n = 301) and 35% RP/V (n = 159). The median follow-up period for patients who underwent complete resection was 42 months (range, 1 to 194 months). We found that RP/V site is a poor prognosticator that is independent of patient sex and age; tumor size, grade, and margin; and recurrent presentation. Sixty-nine percent of patients with RP/V tumors who died had local disease only and no distant metastasis at the time of death. CONCLUSION: In liposarcoma, tumor location exerts as strong an influence on prognosis as biology. In contrast to extremity liposarcoma, LR without distant metastasis often results in death for patients with RP/V tumors. For these patients, local control accomplished by complete surgical resection ± adjuvant radiation therapy should impact strongly on DSS.

APA, Harvard, Vancouver, ISO, and other styles

36

Staege, Martin S., and Daniela Max. "Genetics and Epigenetics of the TET-ETS Translocation Network." Genetics & Epigenetics 2 (January 2009): GEG.S2815. http://dx.doi.org/10.4137/geg.s2815.

Full text

Abstract:

In the present paper we review the translocation network involving TET and ETS family members with special focus on the Ewing family of tumors. FUS (fusion, involved in t(12;16) in malignant liposarcoma = TLS, Translocated in liposarcoma), EWSR1 (Ewing sarcoma breakpoint region 1) and TAF15 (TATA box-binding protein-associated factor, 68-KD) are the three human members of the TET family of RNA binding proteins. In addition, two EWSR1 pseudogenes are present in the human genome. TET family members are involved in several oncogenic gene fusions. Five of the 18 known fusion partners belong to the E26 (E twenty-six, ETS) family of transcription factors. Gene fusions between TET or ETS family members and other fusion partners link these gene fusions to a large network of oncogenic gene rearrangements.

APA, Harvard, Vancouver, ISO, and other styles

37

Chow, W. A., S. Guo, and F. Valdes-Albini. "HIV protease inhibitor (PI) therapy for liposarcoma." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 9564. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.9564.

Full text

Abstract:

9564 Background: Liposarcomas are the second most common soft-tissue sarcoma. Highly-active anti-retroviral therapy (HAART) with HIV PIs results in “HIV-1 protease inhibitor associated lipodystrophy syndrome,” characterized by peripheral fat wasting, central fat accumulation, insulin resistance, and hyperlipidemia. Based upon this syndrome, we hypothesized that HIV PIs might represent a novel liposarcoma therapy. Methods: SW872, LiSa-2, and FU-DDLS-1 liposarcoma, and control 293 embryonic kidney and HT1080 fibrosarcoma cell lines were treated with HIV PIs and subjected to cellular and molecular assays. Results: Clonogenic assays with SW872 cells using HIV PIs (saquinavir, ritonavir, indinavir, nelfinavir, and amprenavir) were performed. Nelfinavir demonstrated the most potent clonogenic inhibition without affecting 293 and HT1080 clonogenicity, and was studied further. Nelfinavir inhibited SW872 and LiSa-2 proliferation dose-dependently, and HT1080 proliferation at the highest concentration, without affecting FU-DDLS-1 nor 293 proliferation. Nelfinavir induced a G1 cell cycle arrest in SW872 and HT1080, but not in 293 cells. It also induced dose-dependent apoptosis in SW872, but not in 293 nor HT1080 cells. Western analyses for sterol regulatory element binding protein-1 (SREBP-1) expression, a key transcriptional regulator of fatty acid and cholesterol synthesis, were performed. Nelfinavir induced expression of SREBP-1 in nelfinavir-sensitive SW872 and LiSa-2 cells, and modestly in HT1080 cells, but not in insensitive FU-DDLS-1 nor 293 cells. Additionally, nelfinavir reduced protein expression of proliferating cell nuclear antigen (PCNA) in sensitive SW872 and LiSa-2 cells, and induced expression of the anti-proliferative protein, p21, as well as pro-apoptotic proteins, Bax and Fas, in a dose-dependent manner. Finally, forced expression of SREBP-1 with a Tet-On inducible SW872 cell line, in the absence of nelfinavir, induced expression of p21, Bax, Fas, reduced expression of PCNA, and inhibited cell proliferation. Conclusions: These studies demonstrate that nelfinavir inhibits cellular proliferation, and induces apoptosis in sensitive-liposarcoma cells through upregulation of SREBP-1. These studies validate nelfinavir as a potential, novel targeted therapy for liposarcoma. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

38

Almoiliqy, Marwan, Abdullah Al-danakh, Mohammed Safi, Mohammed Alradhi, Mahmoud AL-Azab, Salah Adlat, Wanhai Zhou, Aiman Saleh A. Mohammed, and Ahmed Al-maamari. "Surgery Treatment Improved the Overall Survival Rate in Locoregional Myxoid Leiomyosarcoma than Other Myxosarcomas in the United States." Oxidative Medicine and Cellular Longevity 2021 (April 30, 2021): 1–12. http://dx.doi.org/10.1155/2021/9999529.

Full text

Abstract:

Myxosarcomas are rare malignant tumors of soft connective tissues, classified into various subtypes, including myxoid liposarcoma, myxoid chondrosarcoma, and myxoid leiomyosarcoma. In this study, we proposed to study the demographic, tumor characteristics, and overall survival rate and compared the treatment modalities between these cancers. Patient data collected based on locoregional metastasis presentation of the abovementioned tumors with a cutoff study of survival duration up to 10 years were obtained from the SEER database during 1975-2016. Our results indicated that elderly patients and females were more in locoregional myxoid leiomyosarcoma than myxoid liposarcoma and myxoid chondrosarcoma with locoregional metastasis. The white race represented the most patients who suffered from these cancers than other races. The heart is the primary site for the abovementioned cancers, in addition to the female genitals to the myxoid leiomyosarcoma. Myxoid liposarcoma and myxoid chondrosarcoma patients with locoregional metastasis were suffering from grade II, while locoregional myxoid leiomyosarcoma patients with blank grading were due to missed data. Surgery was the most common treatment modality in this study compared with radiotherapy and chemotherapy. Kaplan-Meier analysis showed a significant difference in survival time between the three subtypes by using histology, and myxoid leiomyosarcoma showed prolonged survival than others. Elderly, female, white, unknown grade, surgery, no radiation, and no chemotherapy variables were independent factors associated with overall survival among these cancers. Multivariate analysis also showed significant differences in overall survival between the three tumors by histology, and myxoid leiomyosarcoma was with a better prognosis than others. Multivariate analysis of locoregional myxoid leiomyosarcoma showed the statistical significance of black race, grade, and radiotherapy, indicating them as independent prognostic factors of locoregional myxoid leiomyosarcoma. We conclude that surgery was the primary treatment modality against these cancers than radiotherapy and chemotherapy. And the locoregional myxoid leiomyosarcomas showed a better prognosis and higher survival rate than locoregional myxoid liposarcoma and locoregional myxoid chondrosarcoma.

APA, Harvard, Vancouver, ISO, and other styles

39

Chowdhry, Varun, Saveli Goldberg, Thomas F. DeLaney, Gregory M. Cote, Ivan Chebib, Jason Kim, Santiago A. Lozano-Calderón, and Karen De Amorim Bernstein. "Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy." Sarcoma 2018 (November 1, 2018): 1–6. http://dx.doi.org/10.1155/2018/8029157.

Full text

Abstract:

Introduction. Myxoid liposarcoma (MLS) is a subtype of liposarcoma characterized morphologically by lipomatous differentiation with a myxoid stroma. The purpose of this study was to review clinical and pathological information for patients treated for MLS at our institution to better understand neoadjuvant and adjuvant therapy. Materials and Methods. An institutional database of sarcomas was queried for patients who were treated for MLS at our institution between 1992 and 2013. Survival curves were constructed using Kaplan–Meier analysis, and univariate and multivariate statistics were performed using the Cox-proportional hazards model and using linear regression. Results. A total of 85 patients with myxoid liposarcoma were identified. The mean and median histologic response rate to treatment for patients who received preoperative radiation therapy was 77.6%. Five-year disease-free survival, distant metastasis-free survival, local recurrence-free survival, and overall survival were 78.6% (95% CI: 67.8–86.1), 84.7% (95% CI: 74.5–91.0), 95.6% (95% CI: 86.9–98.6), and 87.5% (95% CI: 77.2–93.3) respectively. On univariate analysis, there was a trend towards higher necrosis or treatment response rates in patients who received concurrent chemotherapy, 84.7% (95% CI: 75.9–93.4) and 69.5% (95% CI: 55.1–83.8), p=0.061. Tumor size was associated with inferior disease-free and overall survival. Hazard ratio for disease-free survival is 1.08 (per cm) (95% CI: 1.01–1.16), p=0.019. Conclusions. Myxoid liposarcoma exhibits histological response to chemotherapy and radiation therapy. Tumor size appears to be greatest predictor of long-term disease control and overall survival. We were not able to show that chemotherapy provides a clinical benefit with regard to local control, disease-free survival, or overall survival. However, it is important to note that the selected usage of chemotherapy in the highest risk patients confounds this analysis. Further investigation is needed to help better determine the optimal use of chemotherapy in this group of patients.

APA, Harvard, Vancouver, ISO, and other styles

40

Xu, Chang, Liang Yan, Xiaoya Guan, Zhen Wang, Jianhui Wu, Ang Lv, Daoning Liu, et al. "Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma." International Journal of Biological Sciences 18, no. 13 (2022): 5038–55. http://dx.doi.org/10.7150/ijbs.70083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Trinkle, Randy. "Use of EMLA as an adjunct for burning pain associated with a liposarcoma." Journal of Oncology Pharmacy Practice 4, no. 2 (June 1998): 121–24. http://dx.doi.org/10.1177/107815529800400204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Pérez-Mancera, P. A., and I. Sánchez-García. "Understanding mesenchymal cancer: the liposarcoma-associated FUS–DDIT3 fusion gene as a model." Seminars in Cancer Biology 15, no. 3 (June 2005): 206–14. http://dx.doi.org/10.1016/j.semcancer.2005.01.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Mitomi, Mutsumi, Kazumi Kimura, Yasuyuki Iguchi, Akihiro Hayashida, Hirotake Nishimura, Isao Irei, Makoto Okawaki, and Hiroaki Ikeda. "A Case of Stroke due to Tumor Emboli Associated with Metastatic Cardiac Liposarcoma." Internal Medicine 50, no. 14 (2011): 1489–91. http://dx.doi.org/10.2169/internalmedicine.50.5071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Li, Chengfang, Yaoyuan Shen, Yan Ren, Wei Liu, Man Li, Weihua Liang, Chunxia Liu, and Feng Li. "Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma." Human Pathology 55 (September 2016): 143–50. http://dx.doi.org/10.1016/j.humpath.2016.05.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Davis, Jessica L., James P. Grenert, and Andrew E. Horvai. "Loss of Heterozygosity and Microsatellite Instability Are Rare in Sporadic Dedifferentiated Liposarcoma: A Study of 43 Well-Characterized Cases." Archives of Pathology & Laboratory Medicine 138, no. 6 (June 1, 2014): 823–27. http://dx.doi.org/10.5858/arpa.2013-0236-oa.

Full text

Abstract:

Context.—Defects in mismatch repair proteins have been identified in Lynch syndrome–associated liposarcomas, as well as in rare sporadic sarcomas. However, it is unclear if mismatch repair defects have a role in sarcoma tumorigenesis. Microsatellite instability is a surrogate marker of mismatch repair defects. Objectives.—To determine whether sporadic dedifferentiated liposarcomas display microsatellite instability and, if so, to evaluate whether such instability differs between the lipogenic and nonlipogenic components of these tumors. Design.—The diagnoses of conventional dedifferentiated liposarcoma were confirmed by a combination of morphologic, immunophenotypic, and molecular studies. Standard fluorescence-based polymerase chain reaction, including 5 mononucleotide microsatellite markers (BAT25, BAT26, NR21, NR24, and MONO27), as well as 2 pentanucleotide repeat markers (Penta C and Penta D), was used to test for instability and loss of heterozygosity. Results.—We demonstrated only a single case (1 of 43) with microsatellite instability at one mononucleotide marker. No sarcomas showed high-level microsatellite instability. However, loss of heterozygosity at the pentanucleotide markers was observed in 8 of 43 cases. The presence of loss of heterozygosity was overrepresented in the nonlipogenic (dedifferentiated) components compared with the paired lipogenic (well differentiated) components. Conclusions.—Mismatch repair defects do not contribute to sporadic dedifferentiated liposarcoma tumorigenesis. Whether the observed loss of heterozygosity drives tumorigenesis in liposarcoma, for example by affecting tumor suppressor or cell cycle regulator genes, remains to be determined.

APA, Harvard, Vancouver, ISO, and other styles

46

Campanella, Nathália C., Valter Penna, Lucas Faria Abrahão-Machado, Adriana Cruvinel-Carloni, Guilherme Ribeiro, Paula Soares, Cristovam Scapulatempo-Neto, and Rui M. Reis. "TERT Promoter Mutations in Soft Tissue Sarcomas." International Journal of Biological Markers 31, no. 1 (January 2016): 62–67. http://dx.doi.org/10.5301/jbm.5000168.

Full text

Abstract:

Introduction Oncogenic hotspot mutations in the promoter region of the TERT gene have been identified in several cancer types as being associated with a worse outcome. Additionally, a polymorphism (rs2853669) in the TERTpromoter region was reported to modify the survival of TERT-mutated patients. Our aim is to determine the frequency of c.-124 C>T and c.-146 C>T TERT mutations and to genotype the rs2853669 polymorphism in a series of 68 soft tissue sarcomas (STS) comprising 22 histological subtypes. Methods PCR was performed, followed by direct sequencing of a fragment of TERT containing the hotspots and the rs2853669. Results We found TERTmutations in 4/68 (5.9%) STSs including 1 pleomorphic liposarcoma (1/1), 1 dedifferentiated liposarcoma (1/1) and 2 myxoid liposarcomas (2/9). The variant C allele of rs2853669 was found in 54.8% (34/62) of all STSs and in 75% (3/4) of TERT-mutated cases. TERT mutations were associated with younger age, and the C allele of the rs2853669 was associated with high histological grade (2 and 3). No association was found between TERT mutation status or rs2853669 genotype and patient prognosis. Conclusions We showed that TERT promoter mutation is not a recurrent event in STS and is present in particular histological subtypes.

APA, Harvard, Vancouver, ISO, and other styles

47

Klement, Giannoula L., David Cervi, Tai-Tung Yip, Judah Folkman, and Joseph Italiano. "Platelet PF-4 Is an Early Marker of Tumor Angiogenesis." Blood 108, no. 11 (November 16, 2006): 1476. http://dx.doi.org/10.1182/blood.v108.11.1476.1476.

Full text

Abstract:

Abstract Early tumor detection and treatment is one of the most important determinants of cancer survival. We reported previously, that a ‘platelet angiogenesis proteome’ can detect clinically occult tumors in mice. We now present evidence that changes in platelet content of platelet factor-4 (PF-4) can be a consistent predictor of tumor growth across a spectrum of cancers. The differentially expressed protein was initially identified as a ~8200Da band by SELDI-ToF analysis. The protein band was isolated and positively identified by peptide sequencing and anti-PF-4 SELDI MS as PF-4. The platelet-associated PF-4 appeared to be up-regulated in early growth of human liposarcoma, mammary adenocarcinoma, osteosarcoma and down-regulated in a RIP-Tag model of pancreatic islet cell carcinoma. A 120 day follow-up study of liposarcoma revealed ≥2-fold increases of platelet-associated PF-4 at 19, 30 and 120 days. Concomitantly, only a ~0.5–1 fold decrease in PF-4 in plasma was observed. There were minimal changes in the plasma of animals bearing other human tumor xenografts. We conclude that platelet-associated PF-4, but not its plasma counterpart, may be a promising marker of early tumor growth or tumor recurrence.

APA, Harvard, Vancouver, ISO, and other styles

48

Chen, Xiaobing, Jun Chen, Ferdinando Carlo Maria Cananzi, Wenjie Li, Vittorio Quagliuolo, Chenghua Luo, and Yinmo Yang. "Prophylactic Ureteral Catheter Placement Appears to Reduce Intraoperative Ureteric Injury During Resection of Primary Retroperitoneal Liposarcoma." Technology in Cancer Research & Treatment 21 (January 2022): 153303382210878. http://dx.doi.org/10.1177/15330338221087831.

Full text

Abstract:

Background: Prophylactic ureteral catheters placement (PUCP) was advocated as an effective strategy for decreasing ureteral morbidities in colorectal surgeries. However, whether it should be routinely used prior to primary retroperitoneal liposarcoma (PRLS) surgeries remains unknown. Methods: It was a retrospective study, conducted at a tertiary sarcoma center. Medical records of patients with PRLS undergoing surgeries from January 2015 through December 2018 were reviewed. Primary endpoint was the rate of ureteral morbidities during and after retroperitoneal liposarcoma resection procedures. Univariate and multivariate analyses determined risk factors associated with ureteral injury (UI) in patients undergoing surgeries. Results: A total of 55 patients of PRLS were included. Fourteen (25.5%) patients underwent PUCP, with 1 UI (7.1%) identified. In 41 patients with no PUCP, 15 (36.6%) exhibited UIs during and post surgeries. There were significant improvements of UIs in group PUCP, compared with patients without PUCP ( P < .05). Resection surgeries combined with colectomy and tumor-ureter relationship were 2 risk factors significantly associated to UIs ( P < .01). Conclusions: PUCP might be an effective way of preventing UIs in patients with PRLS. It could be suggested especially in patients with ureter encased by tumor or anticipated colectomy during the surgical process.

APA, Harvard, Vancouver, ISO, and other styles

49

Sood, Pankaj, Parvesh Kumar, Sarvesh Kumar, Adarsh Kumar, Rajesh Kumar Asrani, and Madhumeet Singh. "A Rare Case of Multicentric Liposarcoma and Associated Reproductive Aberrations in a Nonpregnant Holstein-Friesian Crossbred Cow." Case Reports in Veterinary Medicine 2011 (2011): 1–4. http://dx.doi.org/10.1155/2011/615861.

Full text

Abstract:

A five-and-a-half-year-old Holstein-Friesian crossbred cow was repeatedly treated for termination of overgestation, but without any success. On laparotomy, the site indicating fetal-like ballottement on transrectal palpation was occupied by three to four separate caseous and lobulated masses with adhered uterine horns in the omentum. Separation of the utero-omental adhesions retrieved normal-sized uterine horns into pelvic cavity. The right ovary was cystic. Ultrasonography detected another growth in the ventral abdominal musculature. Histopathologically, the omental growths suggested a pleomorphic type of liposarcoma. Presence of omental and muscular liposarcoma along with deep uterine-omental adhesions and a cystic ovary makes this paper a unique addition to the literature.

APA, Harvard, Vancouver, ISO, and other styles

50

Woo, Yanghee, Susanne G. Warner, Rula Geha, Marianne M. Stanford, Penelope Decarolis, Masmudur M. Rahman, Samuel Singer, Grant McFadden, and Yuman Fong. "The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase." Clinical Medicine Insights: Oncology 15 (January 2021): 117955492199306. http://dx.doi.org/10.1177/1179554921993069.

Full text

Abstract:

Background: Myxoma virus (MYXV) is an oncolytic poxvirus that lacks the gene for 1 of the subunits of ribonucleotide reductase (RR), a crucial DNA synthesis and repair enzyme. The overexpression of RR has been implicated in the invasiveness of several cancers, including soft tissue sarcomas (STS). The purpose of the study was to investigate the oncolytic efficacy of MYXV in STS with different levels of RR expression. Methods: The oncolytic effect of recombinant MYXV was evaluated in 4 human STS cell lines, LS141 (a dedifferentiated liposarcoma), DDLS8817 (a dedifferentiated liposarcoma), RDD2213 (recurrent dedifferentiated liposarcoma), and HSSYII (a synovial sarcoma) using infectivity and cytotoxicity assays. Following the overexpression of RRM2 by cDNA transfection and silencing of RRM2 by siRRM2 in these STS cell lines, the RRM2 expression levels were analyzed by Western blot. Results: We observed a direct correlation between viral oncolysis and RRM2 mRNA levels ( R = 0.96) in STS. Higher RRM2 expression was associated with a more robust cell kill. Silencing the RRM2 gene led to significantly greater cell survival (80%) compared with the control group ( P = .003), whereas overexpression of the RRM2 increased viral oncolysis by 33% ( P < .001). Conclusions: Our results show that the oncolytic effects of MYXV correlate directly with RR expression levels and are enhanced in STS cell lines with naturally occurring or artificially induced high expression levels of RR. Myxoma virus holds promise in the treatment of advanced soft tissue cancer, especially in tumors overexpressing RR.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!